300 related articles for article (PubMed ID: 16919875)
1. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance.
Liu G; Men P; Harris PL; Rolston RK; Perry G; Smith MA
Neurosci Lett; 2006 Oct; 406(3):189-93. PubMed ID: 16919875
[TBL] [Abstract][Full Text] [Related]
2. Chapter 5 - Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease.
Liu G; Men P; Perry G; Smith MA
Prog Brain Res; 2009; 180():97-108. PubMed ID: 20302830
[TBL] [Abstract][Full Text] [Related]
3. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases.
Cui Z; Lockman PR; Atwood CS; Hsu CH; Gupte A; Allen DD; Mumper RJ
Eur J Pharm Biopharm; 2005 Feb; 59(2):263-72. PubMed ID: 15661498
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease.
Liu G; Men P; Kudo W; Perry G; Smith MA
Neurosci Lett; 2009 May; 455(3):187-90. PubMed ID: 19429118
[TBL] [Abstract][Full Text] [Related]
5. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
Devanur LD; Evans RW; Evans PJ; Hider RC
Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease.
Gaeta A; Molina-Holgado F; Kong XL; Salvage S; Fakih S; Francis PT; Williams RJ; Hider RC
Bioorg Med Chem; 2011 Feb; 19(3):1285-97. PubMed ID: 21236688
[TBL] [Abstract][Full Text] [Related]
7. The potential application of iron chelators for the treatment of neurodegenerative diseases.
Hider RC; Roy S; Ma YM; Le Kong X; Preston J
Metallomics; 2011 Mar; 3(3):239-49. PubMed ID: 21344071
[TBL] [Abstract][Full Text] [Related]
8. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.
Bendova P; Mackova E; Haskova P; Vavrova A; Jirkovsky E; Sterba M; Popelova O; Kalinowski DS; Kovarikova P; Vavrova K; Richardson DR; Simunek T
Chem Res Toxicol; 2010 Jun; 23(6):1105-14. PubMed ID: 20521781
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle and iron chelators as a potential novel Alzheimer therapy.
Liu G; Men P; Perry G; Smith MA
Methods Mol Biol; 2010; 610():123-44. PubMed ID: 20013176
[TBL] [Abstract][Full Text] [Related]
10. Role of iron in neurodegenerative disorders.
Berg D; Youdim MB
Top Magn Reson Imaging; 2006 Feb; 17(1):5-17. PubMed ID: 17179893
[TBL] [Abstract][Full Text] [Related]
11. Iron: a new target for pharmacological intervention in neurodegenerative diseases.
Whitnall M; Richardson DR
Semin Pediatr Neurol; 2006 Sep; 13(3):186-97. PubMed ID: 17101458
[TBL] [Abstract][Full Text] [Related]
12. Metal ions, Alzheimer's disease and chelation therapy.
Budimir A
Acta Pharm; 2011 Mar; 61(1):1-14. PubMed ID: 21406339
[TBL] [Abstract][Full Text] [Related]
13. Iron chelators can protect against oxidative stress through ferryl heme reduction.
Reeder BJ; Hider RC; Wilson MT
Free Radic Biol Med; 2008 Feb; 44(3):264-73. PubMed ID: 18215735
[TBL] [Abstract][Full Text] [Related]
14. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents.
Mandel S; Amit T; Bar-Am O; Youdim MB
Prog Neurobiol; 2007 Aug; 82(6):348-60. PubMed ID: 17659826
[TBL] [Abstract][Full Text] [Related]
15. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
Lim CK; Kalinowski DS; Richardson DR
Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle and other metal chelation therapeutics in Alzheimer disease.
Liu G; Garrett MR; Men P; Zhu X; Perry G; Smith MA
Biochim Biophys Acta; 2005 Sep; 1741(3):246-52. PubMed ID: 16051470
[TBL] [Abstract][Full Text] [Related]
17. Combined chelation of bi-functional bis-hydroxypiridinone and mono-hydroxypiridinone: synthesis, solution and in vivo evaluation.
Gama S; Gil M; Gano L; Farkas E; Amélia Santos M
J Inorg Biochem; 2009 Feb; 103(2):288-98. PubMed ID: 19091421
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
[TBL] [Abstract][Full Text] [Related]
19. A Novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities.
Blat D; Weiner L; Youdim MB; Fridkin M
J Med Chem; 2008 Jan; 51(1):126-34. PubMed ID: 18078312
[TBL] [Abstract][Full Text] [Related]
20. Orally active alpha-ketohydroxypyridine iron chelators: studies in mice.
Kontoghiorghes GJ
Mol Pharmacol; 1986 Dec; 30(6):670-3. PubMed ID: 3785144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
